Javelin Biotech
The AI engine Fit Assessment
BetaJavelin Biotech effectively leverages machine learning and pattern discovery to enhance drug discovery and expand therapeutic options.
Blurb
Javelin Biotech is a predictive drug discovery platform intended to make an enhanced prediction of the performance of drugs in humans.
HQ Location
Woburn (United States)
Founded
2018
Employees
11 - 50
Total funding raised
Not available
Last Funding Event
Pre-Seed, January 1, 2019
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Javelin Biotech is a framework for predictive drug discovery designed to improve drug performance prediction in humans. The company's platform enables biopharmaceutical companies to optimize ADME(T) and PD properties, which improve drug discovery and approval of the same, by bringing human-relevant in-vitro data and computational biology or data analytics to pre-clinical drug discovery teams. This accelerates preclinical drug discovery and development by finding human-relevant targets.